Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Adherence and occurrence of fractures after switching to once-monthly oral bisphophonates.

Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA.

Pharmacoepidemiol Drug Saf. 2010 Dec;19(12):1233-40. doi: 10.1002/pds.2048. Epub 2010 Oct 28.

2.

Adoption of once-monthly oral bisphosphonates and the impact on adherence.

Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA.

Am J Med. 2010 Mar;123(3):275-80. doi: 10.1016/j.amjmed.2009.05.017.

3.

Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study.

Harris ST, Reginster JY, Harley C, Blumentals WA, Poston SA, Barr CE, Silverman SL.

Bone. 2009 May;44(5):758-65. doi: 10.1016/j.bone.2009.01.002. Epub 2009 Jan 9.

PMID:
19168160
4.

A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System.

Devine J, Trice S, Finney Z, Yarger S, Nwokeji E, Linton A, Davies W.

Osteoporos Int. 2012 Apr;23(4):1415-24. doi: 10.1007/s00198-011-1729-4. Epub 2011 Jul 23.

PMID:
21786005
5.

Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis.

Cotté FE, Fardellone P, Mercier F, Gaudin AF, Roux C.

Osteoporos Int. 2010 Jan;21(1):145-55. doi: 10.1007/s00198-009-0930-1. Epub 2009 May 21.

6.

Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study.

Sakai A, Ikeda S, Okimoto N, Matsumoto H, Teshima K, Okazaki Y, Fukuda F, Arita S, Tsurukami H, Nagashima M, Yoshioka T.

Osteoporos Int. 2014 Sep;25(9):2245-53. doi: 10.1007/s00198-014-2756-8. Epub 2014 Jun 5. Erratum in: Osteoporos Int. 2014 Oct;25(10):2505-6.

7.

Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.

Cheng LI, Durden E, Limone B, Radbill L, Juneau PL, Spangler L, Mirza FM, Stolshek BS.

J Manag Care Spec Pharm. 2015 Sep;21(9):824-33, 833a.

8.

Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA.

Kishimoto H, Maehara M.

Arch Osteoporos. 2015;10:231. doi: 10.1007/s11657-015-0231-6. Epub 2015 Aug 22.

10.

Factors contributing to compliance with osteoporosis medication.

Kertes J, Dushenat M, Vesterman JL, Lemberger J, Bregman J, Friedman N.

Isr Med Assoc J. 2008 Mar;10(3):207-13.

11.

Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women.

Recker RR, Gallagher R, MacCosbe PE.

Mayo Clin Proc. 2005 Jul;80(7):856-61.

PMID:
16007889
12.
13.

Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis.

Park JH, Park EK, Koo DW, Lee S, Lee SH, Kim GT, Lee SG.

BMC Musculoskelet Disord. 2017 Apr 11;18(1):152. doi: 10.1186/s12891-017-1514-4.

14.

Survey of the utility of once-monthly bisphosphonate treatment for improvement of medication adherence in osteoporosis patients in Japan.

Makita K, Okano H, Furuya T, Urano T, Hirabayashi H, Kumakubo T, Iwamoto J.

J Bone Miner Metab. 2015 Jan;33(1):55-60. doi: 10.1007/s00774-013-0553-7. Epub 2014 Jan 18.

PMID:
24442791
15.
16.

Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates.

Danese MD, Badamgarav E, Bauer DC.

J Bone Miner Res. 2009 Nov;24(11):1819-26. doi: 10.1359/jbmr.090506.

17.

Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.

Wang Z, Ward MM, Chan L, Bhattacharyya T.

Osteoporos Int. 2014 Aug;25(8):2109-16. doi: 10.1007/s00198-014-2738-x. Epub 2014 May 21.

18.

Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures.

Sheehy O, Kindundu C, Barbeau M, LeLorier J.

Osteoporos Int. 2009 Sep;20(9):1583-94. doi: 10.1007/s00198-008-0829-2. Epub 2009 Jan 20.

PMID:
19153677
19.

Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study.

van den Boogaard CH, Breekveldt-Postma NS, Borggreve SE, Goettsch WG, Herings RM.

Curr Med Res Opin. 2006 Sep;22(9):1757-64.

PMID:
16968579

Supplemental Content

Support Center